Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT02905942 Recruiting - Lymphoma Clinical Trials

PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation

Start date: December 2015
Phase: Phase 4
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of PEG-rhG-CSF on the recovery of hematopoietic function after autologous stem cell transplantation in patients with lymphoma.

NCT ID: NCT02905916 Recruiting - Lymphoma Clinical Trials

The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy

Start date: June 2016
Phase: Phase 4
Study type: Interventional

The purpose of the trail is to evaluate the efficacy and safety of PEG-rhG-CSF in primary prophylaxis and secondary prophylaxis of neutropenia after chemotherapy.

NCT ID: NCT02892695 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

Start date: September 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant.

NCT ID: NCT02879526 Recruiting - Clinical trials for Relapse/Refratory Peripheral T Cell Lymphoma

Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma

Start date: August 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate efficacy and safety of Chidamide Combined With Cyclophosphamide,Prednisone,Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma :a Phase II,Single-arm,Open-label, Muti-center Study

NCT ID: NCT02871869 Recruiting - Clinical trials for Diffuse, Large B-Cell, Lymphoma

Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma

Start date: September 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Diffuse large B cell lymphoma (DLBCL), as the most common subtype non-Hodgkin lymphoma (NHL), has great heterogeneity in clinical manifestations, histological morphology and prognosis. R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone) is the gold therapeutic criteria for patients with NHL, and it is also used as the first-line treatment for patients with DLBCL. After treatment, 50%~60%of patients with DLBCL receive complete remission (CR), 30%~40% recurrent and 10% will never be cured due to initial and secondary drug tolerance. This study aimed to explore whether Cinobufacini Tablets had synergistic effect in the treatment of DLBCL, and whether its action was in close association with the positive expression of Na+/K+-ATPase α3, and to observe the rates of adverse reactions induced by Cinobufacini Tablets during treatment.

NCT ID: NCT02869542 Recruiting - Lymphoma Clinical Trials

Institut Paoli Calmettes Lymphoma Database

Start date: January 2000
Phase: N/A
Study type: Observational [Patient Registry]

Database of Institut Paoli-Calmettes patients diagnosed with lymphoma

NCT ID: NCT02859402 Recruiting - Clinical trials for T-cell Non-Hodgkin Lymphoma

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

RRTCLAlloSCT
Start date: December 2016
Phase: Phase 2
Study type: Interventional

Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients. This clinical trial is studying the efficacy and safety of busulfan plus fludarabine as conditioning therapy followed by allogeneic stem cell transplantation (Allo-SCT) in T- and NK/T-cell lymphoma patients who have relapsed or are refractory to previous chemotherapies including autologous transplantation.

NCT ID: NCT02858804 Recruiting - Clinical trials for Mantle Cell Lymphoma

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

BDH-MCL01
Start date: January 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to: 1. determine the efficiency of EDOCH (etoposide,dexamethasone,doxorubicin, cyclophosphamide and vincristine) alternating with DHAP (cisplatin, cytarabine and dexamethasone) regimen combined with rituximab or not in young mantle cell lymphoma patients (age≤65 years); 2. determine the efficiency of rituximab and thalidomide plus prednisone as maintenance regimens.

NCT ID: NCT02858258 Recruiting - Clinical trials for Mantle Cell Lymphoma

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Start date: July 2016
Phase: Phase 3
Study type: Interventional

The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator-assessed failure-free survival.

NCT ID: NCT02856685 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma

A Study of Mitoxantrone Hydrochloride Liposome Infusion

Start date: August 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, multicenter study.